First Drug for Post-Surgery Blood Sugar Drops Succeeds

People who've had bariatric surgery finally have hope for relief from a dangerous side effect that's sent them to the emergency room without warning.

Amylyx Pharmaceuticals announced Tuesday that its experimental drug dramatically reduced severe low blood sugar episodes in patients with post-bariatric hypoglycemia. The condition affects some people after weight loss surgery, causing sudden, dangerous drops in blood sugar that can lead to seizures or unconsciousness.

In the Phase 3 trial, patients taking the drug experienced 55% fewer serious hypoglycemic events compared to those on placebo. That's significantly better than the 35% reduction researchers were hoping to see.

"Any reduction in these hypoglycemic events would be very meaningful for people with PBH and their families," said Amylyx co-CEO Justin Klee. He called the strong results "just so exciting."

Post-bariatric hypoglycemia occurs when blood sugar plummets unexpectedly after eating, sometimes hours after a meal. For patients living with this condition, everyday activities become risky. They never know when their blood sugar might crash, leaving them unable to drive safely, work normally, or care for their families.

Until now, no FDA-approved treatments existed specifically for this condition. Patients have had to manage symptoms through careful diet monitoring and frequent glucose testing, but these measures don't always prevent emergencies.

Why This Inspires

This breakthrough represents years of research paying off for a patient population that's been largely overlooked. As bariatric surgeries have become more common for treating obesity, more people have experienced this challenging complication.

The drug's success means families won't have to live in constant fear of medical emergencies. Parents will gain confidence they won't suddenly lose consciousness while caring for their children. People will be able to return to normal activities without the shadow of unpredictable health crises.

The results also demonstrate how pharmaceutical companies are increasingly developing treatments for conditions that affect smaller patient populations. These patients matter just as much as those with more common diseases.

Amylyx plans to use these results to seek FDA approval, which could make this the first treatment specifically designed for post-bariatric hypoglycemia. For thousands of patients who've felt abandoned by medicine, help is finally on the horizon.